High-risk HPV genotype distribution in HPV co-test specimens: study of a predominantly Midwestern population

Ghosh, Toshi; VandeHaar, Mark A.; Rivera, Michael; Henry, Michael R.

doi:10.1016/j.jasc.2017.09.007

Cited by 5 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HPV16 serotype accounts for over half of HPV-positive malignancies (Supplementary Table 1, Supplemental Digital Content 1, http://links.lww.com/JIT/A623 ). 58 The HPV peptides were mixed individually with 6 purified common HLA class I proteins and assayed via AlphaScreen, a standard method for quantifying biochemical interactions. 59 Positives were retested and plotted as percent control.…”

Section: Resultsmentioning

confidence: 99%

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

Wang

Sandberg

Martin

et al. 2021

Journal of Immunotherapy

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

Wang

Sandberg

Martin

et al. 2021

Journal of Immunotherapy

View full text Add to dashboard Cite

show abstract

“…Ghosh et al . [ 16 ] reported the Other HPV genotypes accounted for the greatest percentage of cytological diagnoses in all categories, and HPV genotype 16 accounted for the second-highest prevalence in all categories in 40,739 women in the Midwestern population of the US. de Sanjose et al .…”

Section: Discussionmentioning

confidence: 99%

“…The highest prevalence of HPV is observed in women aged 20–24 years and it decreases with age. [ 3 5 16 18 20 ] HPV-DNA-positive cases were most common in the age group of 30-39, followed by women under the age of 30. But, the results of the present study are different from those in the literature, but, similar results were obtained in other studies conducted in our country.…”

Section: Discussionmentioning

confidence: 99%

High-risk Human Papillomavirus (hrHPV) Prevalence and Genotype Distribution Among Turkish Women

Geçer¹

2023

Journal of Cytology

View full text Add to dashboard Cite

Purpose: This study aimed to determine the rates of distribution of high-risk HPV (hrHPV) genotypes according to cervical smear samples and biopsy results in a large sample of Turkish women. Methods: The study was conducted with 4,503 healthy volunteer women aged 19-65 years. Samples of cervical smears were collected during the examination and liquid-based cytology was used for the Pap tests. The Bethesda system was used for reporting the cytology. High-risk HPV genotypes including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were investigated in samples. The study cohort was grouped according to age in decades, with comparisons made according to these age groups, Bethesda class, and cervix biopsy results. Results: Among all cases, 903 (20.1%) participants were positive for 1074 hrHPV-DNA genotypes. HPV-DNA positive cases were most common in the 30-39 age group (28.0%), followed by women under the age of 30 (38.5%). HPV genotypes were determined as, in order of frequency: Other hrHPV (n = 590, 65.3%), HPV16 (n = 127, 14.1%), Other HPV + HPV16 (n = 109, 12.1%), HPV 18 (n = 33, 3.6%), and Other HPV + HPV 18 (n = 32, 3.5%). Cervical smears were reported as ASCUS in 304 (6.8%) samples and high-grade squamous intraepithelial lesion (HSIL) in 12 (0.3%) of the samples. Biopsy demonstrated the presence of HSIL in 110 (12.5%) participants, with 644 (73.3%) negative cases. Conclusion: This showed an increasing incidence of Other HPVs besides the known importance of HPV 16 and 18 genotypes as risk factors for cervical cancer.

show abstract

“…Another study in central Mexico reported HPV 51 to be the most prevalent, at 47.2% in HSIL, with HPV 16 second at 30.1% prevalence. 11 A recent Mayo Clinic study 12 reported that hrHPVO genotypes in isolation were the most prevalent, representing 74.3% of all hrHPV-positive specimens. These other genotypes were also associated with the greatest percentage of all different categories of cytologic diagnoses in women aged 30-98 years, comprising 40.9% of HSIL, 58.5% of ASC-H, 76.2% of LSIL, 78.6% of ASC-US, 48.3% of atypical glandular cells of undetermined significance, and 76.2% of NILMPap in a total of 3786 specimens that were positive for at least one hrHPV strain in the study period.…”

Section: Discussionmentioning

confidence: 99%

Women 50 Years and Older With Negative Pap Test and Positive Human Papillomavirus Test for Genotypes Other Than 16 and 18—Follow-up Outcomes

Baban,

Henry,

Long

et al. 2023

J Low Genit Tract Dis

Self Cite

View full text Add to dashboard Cite

Objective A follow-up of women 50 years or older with concomitant positive high-risk human papillomavirus (HPV) genotypes other than 16 and 18 (hrHPVO) and negative Pap test (NILMPap) was conducted to better understand the implications of hrHPVO positivity on potential risk of developing significant high-grade lesions. Material and Methods A retrospective review of 2014 cytology data of patients with co-testing (Pap test and HPV DNA) identified 85 women 50 years or older with NILMPap and hrHPVO+. Results Most patients (63) had repeat co-testing on next follow-up. Of these, 41 patients with persistent hrHPVO+ status, 3 developed cervical intraepithelial neoplasia 2 (CIN2), and 1 CIN3. Nineteen patients were followed with biopsies. Of these, 7 biopsies were abnormal, 5 of which showed low-grade (CIN1) and 2 high-grade (CIN3) histology; none progressed on further follow-up. Three patients were followed with Pap test only, all had NILMPap, and none progressed on further follow-up. In summary, of the 85 patients, 26 developed abnormal histology during follow-up, 6 of whom had high-grade histology (CIN2 and CIN3, 3 each). The 5-year risk of CIN1+ in this cohort was 43.8% and for CIN2+ was 12.3%. The risk of abnormal histology did not differ significantly by prior history of Pap tests, histology, and/or HPV results. Conclusions A persistent positivity for hrHPVO indicated higher likelihood to develop a lesion, and this risk was not reduced for patients 50 and older compared with the published screening population risk.

show abstract

High-risk HPV genotype distribution in HPV co-test specimens: study of a predominantly Midwestern population

Cited by 5 publications

References 18 publications

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

High-risk Human Papillomavirus (hrHPV) Prevalence and Genotype Distribution Among Turkish Women

Women 50 Years and Older With Negative Pap Test and Positive Human Papillomavirus Test for Genotypes Other Than 16 and 18—Follow-up Outcomes

Contact Info

Product

Resources

About